9月27日，2025京津冀创新医学转化与产业促进大赛总决赛在北京城市副中心中关村（通州）创新医学 转化产业园圆满落幕。民生银行北京分行作为战略支持单位全程参与，依托"金融+科技"的专业服务， 为医疗创新成果转化注入强劲动能，助力构建京津冀医产协同发展新格局。 本次大赛以"打造医产协同示范区，发展健康新质生产力"为主题，共吸引国内外405个优质项目参与， 涵盖医疗器械与智能制造、创新医药与生物制品、AI医疗与健康管理、中医药传承创新等四大领域。 历经预审、复赛、总决赛三个阶段，最终35个项目脱颖而出，荣获大赛奖项。 据悉，民生银行北京分行为本次赛事提供战略支持。该行凭借在医疗健康领域的深厚积累，成为链接创 新与产业的关键桥梁。 据介绍，民生银行北京分行始终围绕京津冀'六链五群'产业布局，以金融力量推动创新链、产业链与资 源链深度融合。针对医疗创新企业的跨境发展需求，该行积极响应监管政策，配套"跨境减负"举措，推 出自动化线上收汇、优质企业材料减免以及跨境融资一体化服务，有效缩短企业出海结算周期，并提供 专业化跨境融资支持，构建跨境企业综合服务模式。 针对医疗创新企业在回款周期与订单不匹配、下游融资等方面的痛点， ...

Core Viewpoint - Guangdong Province is advancing healthcare innovation through the integration of AI, surgical robots, and mobile medical solutions to enhance eye health services and address disparities in healthcare access [1][4][9]. Group 1: Technological Innovations - The event showcased innovations in healthcare, including stem cell regeneration, AI diagnostics, surgical robots, and mobile eye clinics [3][4]. - Guangdong is prioritizing technological innovation as a core engine for high-quality healthcare development, focusing on clinical research, result transformation, and innovative medical device applications [10][12]. Group 2: Clinical Research and Development - Guangdong has established a robust clinical research support system, with nearly 50,000 registered clinical research projects and a leading number of approved stem cell clinical research projects in China [13][14]. - The province has implemented national pilot programs to enhance the efficiency of innovative drug and device development [15]. Group 3: Medical Technology Transformation - Guangdong is promoting equal innovation transformation policies for medical institutions and research organizations, including training for medical technology managers and the establishment of "innovation transformation clinics" [16][18]. - The province has introduced 125 types of medical products from Hong Kong and Macau, benefiting over 10,000 patients [22]. Group 4: Breakthroughs in Eye Disease Treatment - The Zhongshan University Eye Center has achieved global leadership in new technologies, drugs, and treatment models, including stem cell technology for congenital cataracts, which has shown a 30% improvement in long-term vision compared to traditional surgery [28][30][31]. - The center has developed the world's first eye drops that can reverse cataracts and new glaucoma medications that break international monopolies, currently in clinical trials [33][34][36]. Group 5: Mobile Healthcare Solutions - To address healthcare access issues, the Zhongshan Eye Center has developed an intelligent medical system utilizing AI and 5G technology, including a smart eye examination vehicle that has served over 16,000 infants [44][47]. - The center is also pioneering a high-precision eye surgery robot that enhances surgical safety and success rates, with plans for remote operations in underserved areas [51][54]. Group 6: Future Plans and Collaborations - The center aims to establish a comprehensive mobile healthcare system, including aerial, satellite, and maritime solutions for eye health, with plans for the first flight of the "Chinese Eye Flying Hospital" by the end of the year [57][60].